Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan vs Treatment of Physician's Choice in Metastatic or Locally Advanced Unresectable Urothelial Cancer
NCT04527991Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in urothelial carcinoma (UC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Overall Survival up to 42 months. Started Jan 2021; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04527991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527991.